FDA Approves Actemra For the Treatment of Rheumatoid Arthritis
FLINT, Mich.— Nov. 07, 2013 —On Monday, October 21, 2013, the U.S. Food and Drug Administration approved a subcutaneous formulation of Actemra® (tocilizumab). This new product was approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Methotrexate is an example of a DMARD. Tocilizumab may be used alone or as a component of a combination therapy regimen consisting of methotrexate or other non-biologic DMARDs. The subcutaneous product will be available as 162 mg single-use prefilled syringes. The product is expected to be available in November 2013.
Actemra® was previously approved as an intravenous (IV) infusion for the treatment of RA, polyarticular juvenile idiopathic arthritis (PJIA), and systemic juvenile idiopathic arthritis (SJIA). Diplomat will be able to distribute this medication when it is available.
For more information about our support services for patients with rheumatoid arthritis, visit our website. You may also contact us directly at 877.977.9118 or, if your inquiry is not urgent, email us at firstname.lastname@example.org.
@SurvivorsDayRT @SurvivorsDay: 4th February is #WorldCancerDay! Spread the message that #WeCanICan take action to help prevent & fight #cancer: https://…2 weeks ago
@DiplomatRxToday is National Wear Red Day. Diplomat employees wore red to support the American Heart Association’s #GoRed for… https://t.co/iparOO4SaF3 weeks ago
@DiplomatRxThriveRx Wins ASPEN Clinical Nutrition Team of Distinction Award https://t.co/IEcr6q9WOr3 weeks ago
@rebekahwarrenRT @rebekahwarren: As MI Legislative Cancer Caucus Co-Chair I was honored to visit @DiplomatRx yesterday to learn how specialty pharmacies…3 weeks ago
@flintandgeneseeRT @flintandgenesee: We're partnering with @DiplomatRx to introduce local high school students to the health care industry's many career op…4 weeks ago